Background: Standard treatment for deep venous thromboembolism involves parenteral anticoagulation overlapping with a vitamin K antagonist, an approach that is effective but associated with limitations including the need for frequent coagulation monitoring. The direct oral anticoagulant rivaroxaban is similarly effective to standard therapy as a single-drug treatment for venous thromboembolism and does not require routine coagulation monitoring. The aim of this analysis was to project the long-term costs and outcomes for rivaroxaban compared to standard of care (tinzaparin/ warfarin). Methods: A total of 184 patients who were under anticoagulant therapy with warfarin or rivaroxaban for extended deep venous thromboembolism were retrospectively evaluated; 59 received rivaroxaban and 125 received warfarin therapy. Assessments were made on age, gender, place of residence, the duration of anticoagulation, mean international normalized ratio value, the effective rate of international normalized ratio (time in the therapeutic range), bleedingrelated complication rate, duration of hospitalization due to complications, the number of annual outpatient department admission, cost for drug, cost for hospitalization, cost for outpatient department admission and international normalized ratio measurements. Conclusion: This analysis suggests that rivaroxaban has lower costs than warfarin in terms of outpatient department admission and hospital costs due to complications; however, warfarin was more economic when all cost parameters were considered. Time in the therapeutic range was found as 56% for warfarin that should be taken into account while analyzing costs and benefits.
Introduction
Deep venous thrombosis (DVT) is a serious clinical condition that may require long-term treatment. 1 One to two new cases of DVT occur in each 1000 persons annually in a given population. 2 Despite effective acute treatment, the disease may follow a chronic course in a significant proportion of patients. Both local pathologies involving thrombus formation and vascular injury as well as severe systemic conditions resulting from pulmonary embolism in addition to thrombophilia necessitate prolonged anti-coagulation in these patients.
When a decision is made for prolonged anti-coagulation based on the clinical status of the patient, the only therapeutic option that was available for use by clinicians was warfarin until very recently, before the introduction of newer oral anticoagulant agents as an addition to our armamentarium in this condition. 3 Rivaroxaban/apixaban that inhibit Factor Xa and dabigatran that causes direct inhibition of thrombin are agents that have been recently introduced for clinical use and that are reimbursed by the Social Security Institution (SGK) in Turkey. In addition to advantages such as negating the need for long-term monitoring of anti-coagulant effect and significantly reduced potential for food and drug interactions, these agents also have shown satisfactory results in terms of safety and efficacy when compared with warfarin. 4 However, high acquisition cost and absence of antidotes represent major factors limiting their use.
An ideal agent for prolonged anti-coagulation should combine maximum clinical efficacy and ease of use with low complication rate and minimum costs. In this regard, rivaroxaban is being increasingly more frequently used owing to proven clinical efficacy in DVT with a single daily dose as well as a lower rate of bleeding-associated complications as compared to warfarin. 5, 6 On the other hand, high acquisition cost is a major limiting factor precluding more common use.
Although pack cost of a medical treatment per patient may appear to be the single most important determinant of the overall treatment cost, it is several other parameters such as the expenses associated with the monitoring of anti-coagulant treatment, admissions due to complications, additional treatments to achieve effective international normalized ratio (INR) values, and loss of productivity that determine the actual cost per patient. In Turkey, no studies examining the overall cost have been performed until now. In this study, our objective was to compare conventional warfarin and rivaroxaban treatments in terms of the costs associated with hospital care, medications, and loss of productivity in a group of patients receiving prolonged anticoagulant therapy due to chronic DVT.
Methods
Patients attending to the outpatient unit of cardiovascular surgery in our facility in 2014 were retrospectively evaluated using INR follow-up forms and digital hospital database records. Among 248 patients initially screened, 184 were included in the study, of whom 125 and 59 were on warfarin and rivaroxaban, respectively. The study protocol was approved by the institutional local Ethics Committee.
Patients with a minimum anticoagulant therapy duration of one year, chronic DVT as documented by Doppler ultrasound (US), and having routine INR tests done exclusively in our facility were included. Patients without regular INR monitoring, poor compliance to anti-coagulant agents, having INR tests in health facilities other than our center, and unreported complications, or those admitted to other centers were excluded.
INR follow-up forms were used to determine the type of anticoagulant therapy and prescription data recorded in Medula database system were used to confirm the type of medication.
Parameters assessed
Patient parameters included age, gender, place of residency, duration of anti-coagulant treatment, mean INR, effective INR ratio, rate of bleeding associated complications, duration of complication associated admissions, and annual number of outpatient visits.
Since ease of access to health facilities was an important parameter to be assessed, patients were divided into three groups based on their place of residency: village, district, or city center. The mean of all INR values measured during a one-year period was taken as the average INR. An INR between 2.0 and 3.0 was considered effective INR.
Hospital database system was used to determine the annual admissions. Admissions due to elevated INR or bleeding were retrieved from the hospital database. The cause and duration of admission as well as the total invoice amount were determined.
Also the number of total visits to the cardiovascular outpatient unit was recorded. Other emergency room visits or outpatient visits than those associated with INR monitoring or bleeding were not considered.
Cost-related parameters were as follows: monthly cost of medication pack, cost of outpatient INR monitoring, cost of admission and treatment due to bleeding-related complications, cost of low molecular weight heparin (LMWH) due to ineffective INR, and costs associated with loss of productivity.
The amount stated in the invoice for warfarin (Coumadin Õ ) and rivaroxaban (Xarelto Õ ) packs were retrieved from SGK records. The annual treatment cost for Coumadin was 23.32 USD (based on a 5 mg daily dose) and 362.6 USD for Xarelto (based on a 20 mg daily dose).
The amount of invoice for a single patient insured by SGK attending to our facility only for routine INR monitoring was 18.66 USD at the time of study. This amount was multiplied by the total number of outpatient visits to yield the annual cost of INR monitoring.
The cost of admission due to bleeding-related complications and the total amount of invoice for each patient were retrieved from the electronic database system. When INR value fell below 1.9, warfarin dose was increased and tinzaparine (subcutaneous route, once daily, on a kg basis) was prescribed for three consecutive days. The cost of three doses of tinzaparine (Innohep Õ ) was 15.75 USD at the time of the study. Also calculated was the number of annual outpatient visits and duration of work absenteeism after hospital stay. The cost equivalent of the loss of productivity during work absenteeism was calculated on the basis of the minimum monthly wage of 316.35 USD, as declared by the Ministry of Labor and Social Security. Thus, the cost of loss of productivity was based on the following formula: 14.38 USD/day Â number of days off.
Statistical analyses SPSS v16.0 software package (SPSS Inc., Chicago, IL, USA) was used for the statistical analyses. Continuous variables were expressed as mean AE standard deviation, while categorical variables were presented as the percent frequency. One-Way ANOVA was used for comparisons involving more than two groups. Post-hoc tests were performed with Tukey's test. Categorical variables were assessed using chi-square test. A p-value of less than 0.05 was considered to signify statistical significance.
Results
Both groups had similar demographic characteristics (Table 1) . Of the 184 study participants, 125 were on warfarin treatment. The mean age of warfarin group was 57 AE 14.9 years and 49 of them (39.2%) were females. Rivaroxaban group was slightly older (62.3 AE 11.9 y), and there were 22 females (37.2%) in this group. Thus, there were more males and the mean age was slightly higher in rivaroxaban group, although the difference did not reach statistical significance. However, a significant difference was found between the two groups with regard to place of residency (p < 0.001). Also, the average duration of anti-coagulant therapy was significantly longer in the warfarin group (p ¼ 0.001).
The proportion of patients achieving effective INR (2.0-3.0) in warfarin group within one year was 57.62 AE 22.15%. Patients with an INR < 1.9 were given subcutaneous tinzaparine for three consecutive days with a per kg basis dose calculation, and were invited for a follow-up visit one week later. An average of 4.69 AE 2.95 packs of tinzaparine was used per patient. In order to evaluate factors with a potential impact on effective INR, patients were sub-grouped based on age, gender, and place of residency, and a within-group assessment was performed (p ¼ 0.691, 0.352, and 0.343, respectively). Comparisons regarding the place of residency in post-hoc tests showed no significant differences. In summary, no significant association was found between the proportion of patients with effective INR values and age, gender, and place of residency (Table 2) .
Average annual drug acquisition cost was significantly lower in warfarin group than in rivaroxaban group (p < 0.001). The average cost of tinzaparine treatment prescribed for cases (4.69 AE 2.95 packs per Table 3 ).
The average annual number of cardiovascular surgery outpatient clinic visits and occasions of INR monitoring were significantly higher in the warfarin group (p < 0.001). Accordingly, the annual average outpatient costs for the warfarin group patients was 147.09 AE 78.002 USD vs. 62.32 AE 19.79 USD in rivaroxaban group, the difference being statistically significant (p < 0.001) ( Table 3) .
The frequency of bleeding-associated complications that required hospitalization was significantly higher in the warfarin group (p ¼ 0.001), in which there were 22 such complications in 21 patients. The most frequent reason for admission was the presence of severe ecchymosis with an INR exceeding 7.0 in 12 patients (9.6%). Other complications included hematuria (1.6%), severe epistaxis (3.2%), and gastrointestinal bleeding (2.4%). In the rivaroxaban group, there was one patient who needed admission due to gastrointestinal bleeding. The average cost associated with hospitalization in the warfarin group per admission was 152.23 USD. When the total cost was allocated to the overall group of warfarin patients (i.e. 125 patients), the annual cost of hospitalization per patient was 26.79 USD. The cost associated with the single admission in rivaroxaban group was 150.33 USD, which corresponded to an annual cost of 2.54 USD per patient in the rivaroxaban group. Thus, the costs associated with hospital admission per patient was significantly higher in warfarin group than in rivaroxaban group (p ¼ 0.007). Also, the two groups differed significantly in terms of the duration of hospitalization due to complications (p ¼ 0.022) ( Table 3) .
The costs associated with loss of productivity were also significantly higher in the warfarin group owing to high admission rate and outpatient visits (p < 0.001) ( Table 3 ).
The classification of the types of cost regarding clinical decisions is shown in Table 4 . When all costs are combined, comparison of warfarin and rivaroxaban yielded a significantly lower overall cost for warfarin (p < 0.001). On the other hand, excluding the annual drug acquisition costs, rivaroxaban performed significantly better than warfarin when costs of outpatient visits, bleeding-related complication (BRC)-associated treatment costs, and loss of productivity were considered as a group (p < 0.001). Also, total hospital costs (outpatient þ admission) were significantly lower in the rivaroxaban group than in the warfarin group (p < 0.001).
A comparison of the overall cost (drug, outpatient, admission) in individuals aged !65 and <65 years was also performed. In terms of outpatient and admission costs, rivaroxaban was superior in both age groups (Table 5) . No comparison for the loss of productivity was made for these age groups.
Discussion
DVT is a condition associated with high treatment costs both for outpatient and inpatient services. The first oral anticoagulant agent indicated for the treatment of chronic as well as recurrent DVT. 7, 8 The EINSTEIN study has confirmed the efficacy and safety of rivaroxaban in addition to is advantages in terms of the ease of use and treatment monitoring both for the physician and the patient. In this study, examining the economic dimensions and cost of the treatment in patients undergoing prolonged treatment for DVT, the annual drug acquisition cost of rivaroxaban was found to be higher than that of warfarin, although with respect to non-drug costs and inpatient costs rivaroxaban showed a marked superiority over warfarin.
Younger patients and patients residing in city centers were more likely to be warfarin users in our study, which may be related with the need for frequent dose monitoring and close supervision in that treatment. This finding is also in line with the fact that the primary condition for reimbursement of rivaroxaban therapy by the social security institution is the failure to achieve effective INR range in successive measurements. It is not surprising to observe that elderly population may experience difficulties in achieving the target INR due to a variety of factors.
A major issue with warfarin in the treatment of DVT is the requirement to maintain a therapeutic INR range between 2 and 3. Inconsistent INR values have been associated with morbidities (recurrent or ineffectively treated DVT/non-major bleeding) and mortality (pulmonary embolism/major bleeding). The duration of INR within the therapeutic range (TTR) is an indication for the efficacy of warfarin treatment. In developed countries such as the USA, Canada, and Japan, the TTR has been reported to be around 65-70%. 9, 10 In the WATER study from our country involving patients with atrial fibrillation, 42.3 AE 18% of the subjects had an effective INR. 11 In another multi-center study from Turkey, i.e. AFTER, the proportion of patients with effective INR was 41.3%. 12 In the current study, TTR was 57.62 AE 22.15%. A persistent failure to achieve effective INR leads to an inadequate therapeutic effect and consequent complications and treatment delays. This TTR value obtained in our study compares favorably with previous reports and probably results from the fact that these patients comprising the study population were followed through a robust monitoring system and by a single physician, and also from the fact that no other cardiovascular surgery centers are present in the vicinity and an individual INR monitoring file is made available for each patient. A TTR around 50% despite this close and effective follow-up system indicates the challenges associated with warfarin use.
Similar to other countries, the acquisition cost of rivaroxaban is higher than warfarin also in Turkey. 5, 13 The annual cost of rivaroxaban use for each patient is nearly 15-fold higher as compared to warfarin. Therefore, drug acquisition cost is the most important determinant of the overall cost of DVT treatment with rivaroxaban. Even when the additional costs imposed by tinzaparine administration in warfarin users with an INR below 2 is considered, the cost of rivaroxaban treatment remains high (approximately 5-fold).
A major problem in DVT patients undergoing anticoagulant therapy is the risk of bleeding, which represents a major cause of morbidity associated with increased hospital admission and cost. Previous studies have reported similar rates of bleeding with warfarin and rivaroxaban treatment. For instance, in EINSTEIN DVT study, rivaroxaban and warfarin had similar rates of first major bleeding and clinically relevant non-major bleeding. 7 Again, the ROCKET study found no difference between warfarin and rivaroxaban in terms of bleeding incidence among AF patients. 14 In another study involving patients on multiple medications, rivaroxaban was found to be well tolerated and associated with lower risk of bleeding than warfarin, owing to reduced predisposition for drug interactions. 15 In our study, patients on warfarin therapy had higher rates of bleeding-related complications, leading to higher rates of hospital admission, outpatient visit, and loss of productivity. This not only leads to increased costs but also reduces the quality of life.
The costs associated with the loss of productivity were calculated based on the minimum wages. When one considers the possibility that some of the patients could have a higher income level, then it follows that the actual cost associated with warfarin treatment might have been higher. There was only one patient with bleeding-related complications in the rivaroxaban group. From an overall cost view, rivaroxaban seems less favorable due to high drug acquisition cost. However, warfarin was associated with higher non-medication costs, mainly due to increased number of outpatient visits and bleeding complications. Cost analyses from other countries also suggested a better profile for rivaroxaban than warfarin/ LMWH in both DVT treatment and prophylaxis. 6, 13, 16, 17 In those analyses based on a Markov model, all DVT-related costs were considered. In Turkey, such an analysis does not seem feasible, however, owing to inadequate data.
Study limitations
The risk spectrum in anticoagulant treatment for DVT has bleeding-related complications on one end, and thromboembolic and local complications on the other end. Pulmonary embolism and post-thrombotic syndrome represent two main complications in this regard. The cost analysis for these two serious complications poses significant technical challenges. Therefore, the costs of non-bleeding complications and post-thrombotic syndrome were not considered in our analysis, being a major limitation. Nevertheless, these results demonstrate the cost difference without considering the cause and process. Another limitation is the small sample size, probably leading to a smaller representation of complications and costs potentially associated with anti-coagulant use. A study with a larger sample size could yield different results due to the inclusion of other costly complications such as strokes and major or intracranial bleedings. Patients' attendance to another medical center for complications may also confound the results. Although this was a potential limitation, our facility is the only tertiary health center with cardiovascular surgery units and highest patient turnover in the close vicinity. Thus, 112 emergency services primarily and directly transport a great majority of the emergent cases to our facility, minimizing this limitation.
Conclusion
Although rivaroxaban use is associated with higher overall costs due to higher acquisition costs, it represents a more economical alternative to warfarin with regard to non-medication and inpatient service costs. Despite advantages of rivaroxaban over warfarin such as ease of use, absence of a need for monitoring, and low potential of food/drug interactions, it has a more unfavorable profile than warfarin in terms of coverall cost due to high acquisition costs.
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